gemcitabine + mitoxantrone + rituximab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Conditions
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Trial Timeline
Dec 1, 2004 → Jan 1, 2008
NCT ID
NCT00656084About gemcitabine + mitoxantrone + rituximab
gemcitabine + mitoxantrone + rituximab is a phase 2 stage product being developed by Eli Lilly for Relapsed or Refractory Mantle Cell Lymphoma (MCL). The current trial status is completed. This product is registered under clinical trial identifier NCT00656084. Target conditions include Relapsed or Refractory Mantle Cell Lymphoma (MCL).
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Mantle Cell Lymphoma (MCL) were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00656084 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed or Refractory Mantle Cell Lymphoma (MCL)